好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effect of Probiotics on Oxidative, Cognitive and Metabolic Outcomes in Alzheimer’s Disease: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Aging, Dementia, and Behavioral Neurology
P12 - Poster Session 12 (11:45 AM-12:45 PM)
3-014

This study aims to analyze the probiotic's effect on neurocognitive function and markers of oxidative stress in Alzheimer's disease (AD) patients.

AD, being a progressive neurodegenerative disease, constitutes nearly 70% of all the cases related to dementia. Different oxidative stress reduction therapies are being discussed for AD including probiotics.

PubMed, Cochrane Central, and ScienceDirect were searched till September 2024. The cognitive outcome of interest was the Mini-Mental State Examination (MMSE) score while the metabolic and oxidative outcomes of interest were levels of glutathione (GSH), nitric oxide (NO), malondialdehyde (MAD), total antioxidant capacity (TAC), homeostatic model of assessment for insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), triglycerides (TAG) and total cholesterol. Statistical analysis was performed on Review Manager version 5.4.1 employing a random effects model. The Cochrane RoB 2.0 tool was used for quality assessment.

Five randomized clinical trials were included in the final analysis. The results depict that the MMSE score (MD = 2.49; 95% CI:[0.44,4.53] ; p = 0.02; I2 = 85%) and GSH levels (MD = 17.78 µmol/L, 95% CI: [3.07,32.50]; p=0.02; I2=0%) were significantly higher in the probiotics group. Probiotics also resulted in reduced MAD (MD = -1.54 µmol/L, 95% CI;[-2.31,-0.78] ; p<0.0001; I2 =95%), HOMA-IR (MD =-0.30, 95% CI:[-0.55,-0.05]; p=0.02; I2 =0%) and an increase in QUICKI (MD =0.01, 95% CI:[0.00,0.01]; p=0.03; I2 =0%) levels compared to placebo. Other outcomes like TAC (MD =-0.80 mmol/L, 95% CI:[-101.78,100.19]; p=0.99; I2 =84%), NO (MD =-0.64 µmol/L, 95% CI:[-2.92,1.63]; p=0.58; I2 =31%), TAG  (MD =-14.55 mg/dL, 95% CI:[-30.73,1.63]; p=0.08; I2 =0%), total cholesterol  (MD =-3.98 mg/dL, 95% CI:[-15.68,7.71]; p=0.50; I2 =0%) were comparable between two groups.

Probiotics improved neurocognitive function in AD patients. They also increased antioxidants like GSH, reduced inflammatory markers like MAD, and lowered insulin resistance.

Authors/Disclosures
Jamir Pitton Rissardo, MD
PRESENTER
Dr. Pitton Rissardo has nothing to disclose.
Abdul Hannan Siddiqui, MBBS Dr. Siddiqui has nothing to disclose.
Hassan Waseem Hassan Waseem has nothing to disclose.
Zain U. Abideen, MBBS Dr. Abideen has nothing to disclose.
Ana Leticia Fornari Caprara, MD Dr. Fornari Caprara has nothing to disclose.
Vishnu V. Byroju, MD (Cooper University Healthcare) Dr. Byroju has nothing to disclose.
Maria Roum Shahzada, MBBS Dr. Roum Shahzada has nothing to disclose.
Saba Yaqoob, MBBS Miss Yaqoob has nothing to disclose.
Zulfiqar H. Jogezai, MBBS, medical student Mr. Jogezai has nothing to disclose.
Muhammad Moosa, MBBS Dr. Moosa has nothing to disclose.
Asma Saif, MBBS Miss Saif has nothing to disclose.
Muhammad Bilal, MBBS Dr. Bilal has nothing to disclose.
Fizza Batool, MBBS Ms. Batool has nothing to disclose.
Areeba Ehsan, MBBS Dr. Ehsan has nothing to disclose.
Muhammad Shoaib, MBBS Mr. Shoaib has nothing to disclose.
Sania Aimen, MBBS Dr. Aimen has nothing to disclose.